1. IGF1R- and ROR1-Specific Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas 
Haein Park, PhD, Xin Huang, MD, Joseph Greene, BA, James Pao, BA, Erin Mulvey, BA, Sophia X. Zhou, Deepali Sachdev, PhD, Douglas Yee, MD, Christoph Rader, PhD, Catherine M. Albert, MD, Carl Hamby, PhD, David Loeb, MD, PhD, Mitchell S. Cairo, MD, Xianzheng Zhou, PhD 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 2, Pages S52-S53 (February 2015)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Fig 1
In vitro and In vivo anti-sarcoma activity of IGF1R and ROR1 CART cells. (A) Cytotoxicity assays, (B) Anti-sarcoma activity in a systemic model, SaOS2-fflucN cells (7.5x105) were i.v. injected into NSG mice for 5 days, treated with mockH IGF1R CAR (IGZ) and ROR1 CAR (RGZ)T cells (1x107) on day 6 and 9, and imaged for tumor control on day 11, 17, 24, 31 and 38, (C) Survival benefit of CAR T cells in a local sarcoma model, SaOS2-fflucN (3x105) cells were i.p. injected in NOD/SCID mice, untreated or treated with mock, IGF1R CAR (IGZ) and ROR1 CAR (RGZ)T cells on day 3, 5 and 7 and monitored for survival.
Biology of Blood and Marrow Transplantation  , S52-S53DOI: ( /j.bbmt )
Copyright © Terms and Conditions